12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Atazanavir/ritonavir regulatory update

FDA granted tentative marketing approval to an NDA from Mylan's Mylan Laboratories Ltd. subsidiary for a fixed-dose atazanavir/ritonavir combination to treat HIV/AIDS infection. The product...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >